Physician
Oncology
Dr. Larry W. Kwak, MD
|
|
Give Review
Larry W. Kwak, MD is an expert in the field of Oncology. He researched medicine at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19 in research and 29 in primary care medicine He over the years received 4 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Elected Member". Larry W. Kwak is a published MD. He published 101 publications, including: 'Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.' He accepts all Medicare patients.
Publications
- Mature adipocytes in bone marrow protect myeloma Cells against chemotherapy through autophagy activation.
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell Lymphoma.
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory Lymphoma.
- Detection of classical Hodgkin Lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
- Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin Lymphoma.
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Rush hour traffic: directing T Cells to tumor.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell Lymphomas, including bulky disease.
- Generation of a new therapeutic peptide that depletes myeloid-derived suppressor Cells in tumor-bearing mice.
- Double hit Lymphoma: the MD Anderson Cancer Center clinical experience.
- Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular Lymphoma.
- The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic Cells and protective immunity against B cel...
- FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell Lymphoma.
- Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established Lymphomas.
- The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma.
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular Lymphoma: a single group, open-label, phase 2 trial.
- Osteoblastic niche supports the growth of quiescent multiple myeloma Cells.
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma.
- Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function.
- Immune evasion of mantle cell Lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.
- In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell Lymphoma: targeting the immunoproteasome.
- Nonstereotyped Lymphoma B cell receptors recognize vimentin as a shared autoantigen.
- Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell Lymphoma.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed Lymphoma: a phase II clinical trial.
- p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction.
- Zoledronic acid for prevention of bone loss in patients receiving primary therapy for Lymphomas: a prospective, randomized controlled phase III trial.
- Role of the microenvironment in mantle cell Lymphoma: IL-6 is an important survival factor for the tumor cells.
- PSGL-1/Selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in Myeloma.
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Sub...
- Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell Lymphoma via induction of reactive oxygen species production.
- Temporal and geographic variations of Waldenstrom Macroglobulinemia incidence: A large population-based study.
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/R...
- Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in Myeloma patients.
- Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial.
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell Lymphoma: a phase 1/2 clinical trial.
- Constitutive activation of p38 MAPK in tumor Cells contributes to osteolytic bone lesions in multiple myeloma.
- Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma Cells and shows synergistic anti-myeloma activity with dexamethasone.
- MicroRNA profiling of follicular Lymphoma identifies microRNAs related to cell proliferation and tumor response.
- Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple Myeloma.
- Idiotype Vaccination As Consolidation Therapy: Time for Integration Into Standard of Care for Follicular Lymphoma?
- Bortezomib-resistant nuclear factor ?B expression in stem-like cells in mantle cell Lymphoma.
- Targeting human B-Cell malignancies through Ig light chain specific cytotoxic T lymphocytes.
- Cancer Vaccines: Moving toward Prevention?
- An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell Lymphoma.
- Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma.
- Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin Lymphoma.
- Effect of long-term storage in TRIzol on microarray-based gene expression profiling.
- Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory Cellular responses in rhesus macaques.
- Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antiLymphoma immunity.
- Myeloma Cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
- IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell Lymphoma cells.
- Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat Myeloma.
- Efficient modulation of T-Cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting Cells.
- Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell Lymphoma.
- Roles of idiotype-specific t Cells in myeloma Cell growth and survival: Th1 and CTL Cells are tumoricidal while Th2 Cells promote tumor growth.
- Eight-year experience with allogeneic stem cell transplantation for relapsed follicular Lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide...
- A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell Lymphoma.
- Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma Cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from...
- An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antiLymphoma immunity.
- Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple Myeloma.
- Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor Cells from apoptosis.
- A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.
- A novel proteoliposomal vaccine induces antitumor immunity against follicular Lymphoma.
- Vaccine therapy for B-cell Lymphomas: next-generation strategies.
- Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin Lymphoma.
- Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic Cells by inhibiting p38 or activating MEK/ERK MAPK and neu...
- Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B Cell...
- Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.
- Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell Lymphoma cells.
- Tumor evasion of the immune System: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.
- Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell Lymphoma.
- Monocyte-derived dendritic Cells: a promising armament for immunotherapy in human malignancies.
- Human autologous tumor-specific T-cell responses induced by liposomal delivery of a Lymphoma antigen.
- Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo.
- Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
- Autologous Lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
- A modified human ELISPOT assay to detect specific responses to primary tumor Cell targets.
- Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular Lymphomas identified by reverse phase protein microarray.
- Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-Cell differentiation antigens in healthy individuals and patients with B-Cell maligna...
- Adoptive immunotherapy with antigen-specific T Cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
- Vaccination strategies for Lymphomas.
- Translational development of active immunotherapy for hematologic malignancies.
- Toll-like receptor 4-dependent activation of dendritic Cells by beta-defensin 2.
- DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce Systemic and mucosal immune responses.
- Models for Lymphoma.
- Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma.
- Cloning variable region genes of clonal Lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine.
- Therapeutic Lymphoma vaccines: importance of T-cell immunity.
- Translational development of vaccination strategies in follicular NHL.
- Targeting Cell surface β2 -microglobulin by pentameric IgM antibodies.
- Identification of human idiotype-specific T cells in Lymphoma and myeloma.
- Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell Lymphoma.
- Prospective isolation of clonogenic mantle cell Lymphoma-initiating cells.
- Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines.
- Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and Lymphoma mouse models.
- A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-Cell clones.
- Elevated serum BLyS levels in patients with non-Hodgkin Lymphoma.
Schools
NWU FIENBERG SCH OF MED
Stanford University Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Elected Member
Education
-
Stanford University -
Northwestern University Feinberg School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1134215817 | |
| NPPES Provider LastName | KWAK | |
| NPPES Provider FirstName | LARRY | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 70.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134215817 |
| Last Name Of The Provider | KWAK |
| First Name Of The Provider | LARRY |
| View All |
Similar Doctors
|
|
Dr. Lori A. Leslie, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shamail Butt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Araujo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Banu K. Arun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Hong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Werner A. Bleyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vivian T. Yin, MD
This Doctor is OpenDoctor Recommended.
|